| scholarly article | Q13442814 |
| retracted paper | Q45182324 |
| P356 | DOI | 10.1172/JCI73014 |
| P8608 | Fatcat ID | release_w4jymbuq6rg3vbexkh7rr6nxou |
| P932 | PMC publication ID | 4089447 |
| P698 | PubMed publication ID | 24837434 |
| P5875 | ResearchGate publication ID | 262419132 |
| P50 | author | Yang-Xin Fu | Q57177963 |
| P2093 | author name string | Kipp Weiskopf | |
| Aurelien Marabelle | |||
| Cariad Chester | |||
| Holbrook E Kohrt | |||
| Lieping Chen | |||
| Roch Houot | |||
| A Dimitrios Colevas | |||
| Wen-Kai Weng | |||
| Ronald Levy | |||
| Peder Lund | |||
| Idit Sagiv-Barfi | |||
| John Sunwoo | |||
| Erin Waller | |||
| Debra Czerwinski | |||
| Matthew J Goldstein | |||
| Lori Richards | |||
| Amanda Rajapaska | |||
| Anton Ostashko | |||
| Antonia Mueller | |||
| Emily Troutner | |||
| Jonathan Hebb | |||
| Ruth Lira | |||
| P2860 | cites work | KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. | Q27851616 |
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function | Q43442797 | ||
| CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells | Q44322092 | ||
| Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells | Q45230085 | ||
| Use of adoptive transfer and Winn assay procedures in the further analysis of antiviral acquired immunity in mice protected against Friend leukemia virus-induced disease by passive serum therapy. | Q45795154 | ||
| Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. | Q46151045 | ||
| Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. | Q52548591 | ||
| NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. | Q54109907 | ||
| Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. | Q54532080 | ||
| Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head | Q56688854 | ||
| Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base | Q57949385 | ||
| Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer | Q70505754 | ||
| Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma | Q77387054 | ||
| Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity | Q78346730 | ||
| Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor | Q79856185 | ||
| CD137 promotes proliferation and survival of human B cells | Q82234590 | ||
| Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials | Q84402570 | ||
| Cutting edge: Expression of functional CD137 receptor by dendritic cells | Q28215568 | ||
| The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors | Q33595085 | ||
| Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients | Q33621891 | ||
| CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells | Q33722711 | ||
| An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells | Q33798802 | ||
| 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines | Q33857971 | ||
| Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models | Q33893381 | ||
| Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape | Q34194706 | ||
| A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab | Q34382125 | ||
| Regulation of granulocyte and macrophage populations of murine bone marrow cells by G-CSF and CD137 protein | Q34403700 | ||
| The biology of human natural killer-cell subsets | Q34430869 | ||
| Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype | Q34434169 | ||
| CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies | Q34707604 | ||
| Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors | Q34789146 | ||
| Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer | Q35177848 | ||
| EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma | Q35416013 | ||
| Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer | Q35780315 | ||
| Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement | Q35883004 | ||
| Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. | Q36512532 | ||
| Immunostimulatory monoclonal antibodies for cancer therapy | Q36717901 | ||
| Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies | Q36787500 | ||
| Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients | Q36806268 | ||
| Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer | Q37182719 | ||
| Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion | Q37396078 | ||
| Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo | Q37729194 | ||
| Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies | Q37767871 | ||
| The bidirectional crosstalk between human dendritic cells and natural killer cells | Q37853782 | ||
| Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity | Q37895956 | ||
| CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. | Q39763495 | ||
| In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. | Q39815528 | ||
| Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells | Q39868562 | ||
| Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab | Q39981791 | ||
| Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates | Q40039203 | ||
| A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay | Q40110055 | ||
| Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines | Q40164557 | ||
| CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. | Q40383762 | ||
| The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. | Q40460294 | ||
| Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response | Q40536409 | ||
| Reciprocal activating interaction between natural killer cells and dendritic cells | Q41992239 | ||
| Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells | Q42005335 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cetuximab | Q420296 |
| P304 | page(s) | 2668-2682 | |
| P577 | publication date | 2014-05-16 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Targeting CD137 enhances the efficacy of cetuximab | |
| P478 | volume | 124 |
| Q27012963 | 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity |
| Q28079622 | 4-1BB agonism: adding the accelerator to cancer immunotherapy |
| Q91632541 | A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4+ T and Natural Killer Cells |
| Q57462224 | A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent and Antitumor Activity in Preclinical Models of Small Cell Lung Cancer |
| Q41664652 | A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer |
| Q47752545 | A tribute to the life and career of Holbrook Kohrt |
| Q59136671 | A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity |
| Q26751344 | Advances in targeted and immunobased therapies for colorectal cancer in the genomic era |
| Q38576510 | Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. |
| Q52681590 | Altered Immune-Related Gene Expressions Indicate Oral Cancer Nodal Disease. |
| Q39169351 | An Expanding Role for Immunotherapy in Colorectal Cancer |
| Q64253759 | An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer |
| Q47782325 | Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand |
| Q37222143 | Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity |
| Q38847631 | Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells |
| Q48112970 | Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking |
| Q39190801 | Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma |
| Q38823350 | Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? |
| Q38440279 | Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. |
| Q50043038 | CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer |
| Q28072933 | CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses |
| Q41808416 | CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies |
| Q89776447 | CD137, an attractive candidate for the immunotherapy of lung cancer |
| Q26752277 | Cancer immunotherapy: the beginning of the end of cancer? |
| Q37204600 | Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model |
| Q40457683 | Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. |
| Q35149637 | Classification of current anticancer immunotherapies |
| Q37709902 | Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma. |
| Q92768537 | Co-stimulatory and co-inhibitory pathways in cancer immunotherapy |
| Q34487698 | Combination cancer immunotherapy and new immunomodulatory targets |
| Q90455060 | Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy |
| Q46472020 | Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway |
| Q34978570 | Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. |
| Q59477539 | Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations |
| Q92385628 | Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells |
| Q38698632 | Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy |
| Q90734623 | Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors |
| Q38313664 | Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors |
| Q89956845 | Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer |
| Q38268896 | Emerging biomarkers in head and neck cancer in the era of genomics. |
| Q38912287 | Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment |
| Q26796313 | Enhancing Cancer Immunotherapy Via Activation of Innate Immunity |
| Q38553010 | Evolving synergistic combinations of targeted immunotherapies to combat cancer. |
| Q35764479 | Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. |
| Q35809223 | Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12. |
| Q90218507 | Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers |
| Q97521967 | Harnessing NK Cell Checkpoint-Modulating Immunotherapies |
| Q38757095 | Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab. |
| Q36597479 | Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism |
| Q51436135 | IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation. |
| Q37012676 | Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes |
| Q26775578 | Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect |
| Q64898611 | Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location. |
| Q92344231 | Immune Resistance and EGFR Antagonists in Colorectal Cancer |
| Q38710672 | Immune checkpoint blockade in lymphoid malignancies |
| Q38429240 | Immune modulation in advanced radiotherapies: Targeting out-of-field effects |
| Q26765115 | Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials |
| Q92092322 | Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma |
| Q38821875 | Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop |
| Q51700392 | Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop. |
| Q38675140 | Immunosuppressive cells in tumor immune escape and metastasis |
| Q52902699 | Immunotherapy for Head and Neck Squamous Cell Carcinoma. |
| Q39308337 | Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options |
| Q45998119 | Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. |
| Q47850855 | Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies |
| Q28087719 | Improving natural killer cell cancer immunotherapy |
| Q38991015 | Innate immune mediators in cancer: between defense and resistance |
| Q64076510 | Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
| Q59800415 | Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells |
| Q57796333 | Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab |
| Q36635914 | Models to Study NK Cell Biology and Possible Clinical Application |
| Q28072433 | Molecular targeted therapy for the treatment of gastric cancer |
| Q48228066 | Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice. |
| Q38508211 | NK Cells and Cancer Immunoediting |
| Q101063020 | NK Cells in the Tumor Microenvironment |
| Q92399857 | NK cell expression of Tim-3: First impressions matter |
| Q91992294 | NK cells to cure cancer |
| Q35506745 | NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma |
| Q26772347 | Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy |
| Q107329210 | Natural Killer Cells in Cancer Immunotherapy |
| Q38542034 | Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. |
| Q46047154 | New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone |
| Q38578733 | New Strategies in Human Papillomavirus-Related Oropharynx Cancer: Effecting Advances in Treatment for a Growing Epidemic |
| Q96950741 | New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis |
| Q33809528 | Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients |
| Q57498575 | Nimotuzumab: beyond the EGFR signaling cascade inhibition |
| Q45877184 | Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice. |
| Q99214394 | Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies |
| Q37473163 | Novel anti-EPHA2 antibody, DS-8895a for cancer treatment |
| Q38794338 | Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications |
| Q93008679 | Nuclear-localized costimulatory molecule 4-1BBL promotes colon cancer cell proliferation and migration by regulating nuclear Gsk3β, and is linked to the poor outcomes associated with colon cancer |
| Q39139069 | Oncogenic growth factor signaling mediating tumor escape from cellular immunity |
| Q45895871 | Predicting CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy |
| Q38692084 | Rationale for anti-CD137 cancer immunotherapy |
| Q46113809 | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation |
| Q112691210 | Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway |
| Q39274485 | Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody |
| Q41996352 | Roles for Innate Immunity in Combination Immunotherapies |
| Q42751492 | Routing cancer immunology and immunotherapy from the lab to the clinic 4-5 th March 2014, Center for Applied Medical Research and University Clinic, Pamplona, Spain |
| Q35920773 | STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients |
| Q99552006 | Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer |
| Q91008601 | Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies |
| Q57465671 | Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer |
| Q38390840 | Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. |
| Q39150423 | Targeting NK-cell checkpoints for cancer immunotherapy |
| Q36656097 | Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation? |
| Q38829849 | Targeting natural killer cells in cancer immunotherapy |
| Q33872496 | Targeting secondary immune responses to cetuximab: CD137 and the outside story |
| Q90706071 | The Potential for Cancer Immunotherapy in Targeting Surgery-Induced Natural Killer Cell Dysfunction |
| Q91558469 | The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma |
| Q38743507 | The Role of Targeted Therapy in the Management of Sinonasal Malignancies |
| Q37517482 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia |
| Q38775177 | The future of cancer treatment: immunomodulation, CARs and combination immunotherapy |
| Q28259862 | The future of immune checkpoint therapy |
| Q37351606 | The head and neck cancer immune landscape and its immunotherapeutic implications |
| Q56891562 | The promise and challenges of immune agonist antibody development in cancer |
| Q42558833 | Trial watch: Tumor-targeting monoclonal antibodies for oncological indications |
| Q99407479 | Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy |
| Q49865882 | Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy |
| Q92216419 | Vesicular Antibodies: A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy |
| Q90460925 | What, Why, Where, and When: Bringing Timing to Immuno-Oncology |
| Q92430249 | [Anti-tumor monoclonal antibodies: new insights to elicit a long-term immune response] |
Search more.